Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: Effects on macrophage recruitment, nuclear factor-κB nuclear translocation, and foam cell death

Circulation

Volumn 115, Issue 18, 2007, Pages 2442-2450

  Oumouna Benachour, Karine ^a   Hans, Chetan P ^a   Suzuki, Yasuhiro ^a   Naura, Amarjit ^a   Datta, Rahul ^a   Belmadani, Souad ^a   Fallon, Kenneth ^a   Woods, Cooper ^b   Boulares, A Hamid ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Aorta; Atherosclerosis; Collagen; Free radicals; Inhibitors; Plaque; Vasculature

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; FAT; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOQUINOLINE DERIVATIVE; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CELL MIGRATION; CELL PROTECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA DAMAGE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FOAM CELL; GENE DELETION; GENETIC ASSOCIATION; HETEROZYGOTE; INTIMA; LIPID COMPOSITION; LIPID DIET; LIPOPROTEIN DEFICIENCY; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN STABILITY; RAT; SMOOTH MUSCLE FIBER;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; CELLS, CULTURED; CHEMOKINE CCL2; CHOLESTEROL; COLLAGEN; CROSSES, GENETIC; DIET, ATHEROGENIC; DRUG EVALUATION, PRECLINICAL; FOAM CELLS; GENE EXPRESSION REGULATION; GENOTYPE; HYDROGEN PEROXIDE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISOQUINOLINES; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NECROSIS; NF-KAPPA B; OXIDATIVE STRESS; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; SPECIFIC PATHOGEN-FREE ORGANISMS; THIOPHENES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRIGLYCERIDES;

EID: 34248178529     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.668756     Document Type: Article

References (28)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb. 2003;10:267-274.
3. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med. 2000;28:1780-1794.
4. Moghadasian MH. Experimental atherosclerosis: a historical overview. Life Sci. 2002;70:855-865.
5. Schraufstatter IU, Hyslop PA, Hinshaw DB, Spragg RG, Sklar LA, Cochrane CG. Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A. 1986;83:4908-4912.
6. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A. 1996;93:1753-1758.
7. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation. 2002;106:2680-2686.
8. Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal. 2005;7:1568-1580.
9. Rajesh M, Mukhopadhyay P, Godlewski G, Batkai S, Hasko G, Liaudet L, Pacher P. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun. 2006;350:1056-1062.
10. Pacher P, Mabley JG, Soriano FG, Liaudet L, Szabo C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int J Mol Med. 2002;9:659-664.
11. Szabo C. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions. Curr Vasc Pharmacol. 2005;3:301-303.
12. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation. 2002;106:927-932.
13. Zhang C, Yang J, Jennings LK. Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery. Am J Physiol. 2004;287:H659-H666.
14. Sharp C, Warren A, Oshima T, Williams L, Li JH, Alexander JS. Poly ADP ribose-polymerase inhibitors prevent the upregulation of ICAM-1 and E-selectin in response to Th1 cytokine stimulation. Inflammation. 2001;25:157-163.
15. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose) polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci. 2002;59:1534-1553.
16. Carrillo A, Monreal Y, Ramirez P, Marin L, Parrilla P, Oliver FJ, Yelamos J. Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res. 2004;32:757-766.
17. Boulares AH, Zoltoski AJ, Sherif ZA, Jolly P, Massaro D, Smulson ME. Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma. Am J Respir Cell Mol Biol. 2003;28:322-329.
18. Oumouna M, Datta R, Oumouna-Benachour K, Suzuki Y, Hans C, Matthews K, Fallon K, Boulares H. Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J Immunol. 2006;177:6489-6496.
19. Benko R, Pacher P, Vaslin A, Kollai M, Szabo C. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci. 2004;75:1255-1261.
20. Pellicciari R, Camaioni E, Costantino G, Marinozzi M, Macchiarulo A, Moroni F, Natalini B. Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Farmaco. 2003;58:851-858.
21. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999;274:22932-22940.
22. Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. Curr Opin Lipidol. 2003;14:469-475.
23. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 2005;3:63-68.
24. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, Snyder SH. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A. 1999;96:3059-3064.
25. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25:2255-2264.
26. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG. Oxidant injury of cells: DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest. 1986;77:1312-1320.
27. Chong ZZ, Lin SH, Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res. 2002;39:131-147.
28. Beller CJ, Radovits T, Kosse J, Gero D, Szabo C, Szabo G. Activation of the peroxynitrite-poly(adenosine diphosphate-ribose) polymerase pathway during neointima proliferation: a new target to prevent restenosis after endarterectomy. J Vasc Surg. 2006;43:824-830.